Core Insights - Nutriband is planning to file for FDA approval for its AVERSA™ Fentanyl product in the first half of 2025 [1] - The AVERSA™ technology aims to deter abuse and misuse of transdermal fentanyl patches, potentially improving safety for patients [4][11] - The technology is protected by a broad intellectual property portfolio with patents granted in 46 countries, including major markets [10][15] Company Developments - Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which integrates Nutriband's abuse-deterrent technology into an FDA-approved transdermal system [3] - The company has completed the registration requirements to extend its Chinese patent to Macao, enhancing its intellectual property protection [9] - AVERSA™ Fentanyl is projected to achieve peak annual sales in the U.S. ranging from 200 million [12] Technology Overview - The AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent drug abuse and accidental exposure [4][11] - This technology is designed to maintain accessibility for patients who genuinely need these medications while reducing the risk of misuse [4][11] - The technology's broad patent coverage includes regions such as Hong Kong and Macao, in addition to other major markets [10][15]
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology